A549
|
CC50 |
1555.6 μM
Compound: Acyclovir
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 34425312]
|
BC-3
|
IC50 |
|
Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay
Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay
|
[PMID: 17402726]
|
BHK-21
|
EC50 |
|
Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
|
[PMID: 26443549]
|
BHK-21
|
EC50 |
|
Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
|
[PMID: 25082514]
|
BHK-21
|
EC50 |
|
Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay
|
[PMID: 25082514]
|
BHK-21
|
EC50 |
|
Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay
Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay
|
[PMID: 19482481]
|
BHK-21
|
EC50 |
|
Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay
Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay
|
[PMID: 19482481]
|
BHK-21
|
CC50 |
|
Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay
Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay
|
[PMID: 25082514]
|
BHK-21
|
CC50 |
|
Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay
Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay
|
[PMID: 19482481]
|
BHK-21
|
EC50 |
|
Effective concentration was evaluated against HSV-1 by using serum starved baby hamster kidney cells in a colorimetric viral yield assay.
Effective concentration was evaluated against HSV-1 by using serum starved baby hamster kidney cells in a colorimetric viral yield assay.
|
[PMID: 8863795]
|
BHK-21
|
EC50 |
|
Effective concentration was evaluated against HSV-2 by using serum starved baby hamster kidney cells in a colorimetric viral yield assay.
Effective concentration was evaluated against HSV-2 by using serum starved baby hamster kidney cells in a colorimetric viral yield assay.
|
[PMID: 8863795]
|
BSC-1
|
EC50 |
0.3 μM
Compound: Acyclovir
|
Antiviral activity against Herpes simplex virus type 1 in african green monkey BSC1 cells by plaque reduction assay
Antiviral activity against Herpes simplex virus type 1 in african green monkey BSC1 cells by plaque reduction assay
|
[PMID: 19410465]
|
BSC-1
|
EC50 |
10 μM
Compound: acyclovir
|
Inhibition of HSV1 replication in BSC1 cells by ELISA
Inhibition of HSV1 replication in BSC1 cells by ELISA
|
[PMID: 15615545]
|
BSC-1
|
EC50 |
3.5 μM
Compound: acyclovir
|
Inhibition of HSV1 replication in BSC1 cells by ELISA
Inhibition of HSV1 replication in BSC1 cells by ELISA
|
[PMID: 17004726]
|
CCRF-CEM
|
EC50 |
> 250 μM
Compound: 1, ACV
|
Antiviral activity against HIV1 3B/Lai infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days
Antiviral activity against HIV1 3B/Lai infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days
|
[PMID: 19645484]
|
CCRF-CEM
|
EC50 |
> 250 μM
Compound: 1, ACV
|
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days
|
[PMID: 19645484]
|
CCRF-CEM
|
IC50 |
> 440 μM
Compound: Acyclovir
|
In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity
In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity
|
[PMID: 11814776]
|
Daudi
|
EC50 |
0.33 μM
Compound: acyclovir
|
Inhibition of EBV replication in Daudi cells by viral capsid antigen-ELISA
Inhibition of EBV replication in Daudi cells by viral capsid antigen-ELISA
|
[PMID: 17004726]
|
Daudi
|
EC50 |
1.1 μM
Compound: acyclovir
|
Inhibition of EBV replication in Daudi cells by VCA ELISA
Inhibition of EBV replication in Daudi cells by VCA ELISA
|
[PMID: 15615545]
|
Daudi
|
EC50 |
5.3 μM
Compound: acyclovir
|
Inhibition of EBV replication in Daudi cells by DNA hybridization assay
Inhibition of EBV replication in Daudi cells by DNA hybridization assay
|
[PMID: 15615545]
|
DG-75
|
IC50 |
|
Cytotoxicity against DG75 cells after 120 hrs by MTT assay
Cytotoxicity against DG75 cells after 120 hrs by MTT assay
|
[PMID: 17402726]
|
E6SM
|
EC50 |
0.07 μg/mL
Compound: acyclovir
|
Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture
Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture
|
[PMID: 15481985]
|
E6SM
|
EC50 |
0.07 μg/mL
Compound: acyclovir
|
Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture
Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture
|
[PMID: 15481985]
|
E6SM
|
EC50 |
0.38 μg/mL
Compound: acyclovir
|
Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture
Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture
|
[PMID: 15481985]
|
E6SM
|
EC50 |
48 μg/mL
Compound: acyclovir
|
Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture
Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture
|
[PMID: 15481985]
|
HEL
|
IC50 |
|
The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50%
The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50%
|
[PMID: 10411487]
|
HEL
|
EC50 |
> 1000 μM
Compound: Acyclovir
|
Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay
Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay
|
[PMID: 22858222]
|
HEL
|
CC50 |
> 130 μM
Compound: Acyclovir
|
Cytotoxicity against HEL cells after 3 days by coulter counter analysis
Cytotoxicity against HEL cells after 3 days by coulter counter analysis
|
[PMID: 21232828]
|
HEL
|
CC50 |
> 200 μg/mL
Compound: acyclovir
|
Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days
Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days
|
[PMID: 17869124]
|
HEL
|
CC50 |
> 200 μg/mL
Compound: L-BVDU
|
Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells.
Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells.
|
[PMID: 7877148]
|
HEL
|
CC50 |
> 200 μg/mL
Compound: Acyclovir
|
Cytotoxic concentration reducing HEL cell growth by 50%.
Cytotoxic concentration reducing HEL cell growth by 50%.
|
[PMID: 12217359]
|
HEL
|
CC50 |
> 200 μg/mL
Compound: Acyclovir
|
The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells
The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells
|
[PMID: 10197958]
|
HEL
|
EC50 |
> 200 μM
Compound: acyclovir
|
Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture
Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture
|
[PMID: 15481985]
|
HEL
|
CC50 |
|
Cytotoxic concentration required to inhibit HEL cell growth by 50 %
Cytotoxic concentration required to inhibit HEL cell growth by 50 %
|
[PMID: 11212118]
|
HEL
|
CC50 |
> 200 μM
Compound: 5 (Acyclovir)
|
cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus
cytostatic concentration required to reduce the HEL cell number by 50%. after 5 days in the absence of virus
|
[PMID: 11150169]
|
HEL
|
CC50 |
> 200 μM
Compound: ACV acyclovir
|
The compound was tested for cytotoxic concentration required to inhibit Hel cell growth by 50%
The compound was tested for cytotoxic concentration required to inhibit Hel cell growth by 50%
|
[PMID: 10866384]
|
HEL
|
EC50 |
> 250 μM
Compound: Acyclovir
|
Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
|
[PMID: 32214762]
|
HEL
|
EC50 |
> 250 μM
Compound: Acyclovir
|
Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
|
[PMID: 32214762]
|
HEL
|
EC50 |
> 250 μM
Compound: Acyclovir
|
Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
|
[PMID: 32214762]
|
HEL
|
EC50 |
> 250 μM
Compound: Acyclovir
|
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
|
[PMID: 22459876]
|
HEL
|
EC50 |
> 250 μM
Compound: Acyclovir
|
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
|
[PMID: 22459876]
|
HEL
|
EC50 |
> 250 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
|
[PMID: 22459876]
|
HEL
|
EC50 |
> 250 μM
Compound: Acyclovir
|
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
|
[PMID: 21696963]
|
HEL
|
EC50 |
> 250 μM
Compound: Acyclovir
|
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
|
[PMID: 23603046]
|
HEL
|
CC50 |
> 300 μM
Compound: Acyclovir
|
Cytotoxicity against human HEL cells assessed as reduction in cell growth incubated for 3 days by coulter counter method
Cytotoxicity against human HEL cells assessed as reduction in cell growth incubated for 3 days by coulter counter method
|
[PMID: 33039724]
|
HEL
|
CC50 |
> 300 μM
Compound: Acyclovir
|
Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method
Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method
|
[PMID: 33894564]
|
HEL
|
CC50 |
> 400 μM
Compound: Acyclovir
|
Cytotoxicity against human HEL cells by colorimetric formazan-based MTS assay
Cytotoxicity against human HEL cells by colorimetric formazan-based MTS assay
|
[PMID: 21696963]
|
HEL
|
EC50 |
> 400 μM
Compound: acyclovir
|
Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture
Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture
|
[PMID: 15481985]
|
HEL
|
CC50 |
> 440 μM
Compound: Acyclovir
|
Cytostatic activity against human HEL cells after 3 days by coulter counter method
Cytostatic activity against human HEL cells after 3 days by coulter counter method
|
[PMID: 29945100]
|
HEL
|
CC50 |
> 440 μM
Compound: Acyclovir
|
Cytostatic activity against HEL cells after 3 days by Coulter counting method
Cytostatic activity against HEL cells after 3 days by Coulter counting method
|
[PMID: 29407990]
|
HEL
|
CC50 |
> 440 μM
Compound: Acyclovir
|
Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method
Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method
|
[PMID: 28757102]
|
HEL
|
CC50 |
> 440 μM
Compound: Acyclovir
|
Cytotoxicity against Varicella zoster virus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method
Cytotoxicity against Varicella zoster virus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method
|
[PMID: 26443550]
|
HEL
|
CC50 |
> 444 μM
Compound: Acyclovir
|
Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method
Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method
|
[PMID: 32676147]
|
HEL
|
CC50 |
> 444 μM
Compound: Acyclovir
|
Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method
Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method
|
[PMID: 29670705]
|
HEL
|
CC50 |
> 444 μM
Compound: Acyclovir
|
Cytostatic activity against HEL cells after 3 days by Coulter counting method
Cytostatic activity against HEL cells after 3 days by Coulter counting method
|
[PMID: 29550734]
|
HEL
|
CC50 |
> 444 μM
Compound: Acyclovir
|
Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method
Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method
|
[PMID: 29268134]
|
HEL
|
CC50 |
> 444 μM
Compound: Acyclovir
|
Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method
Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method
|
[PMID: 28682067]
|
HEL
|
CC50 |
> 444.03 μM
Compound: Acyclovir
|
Cytotoxicity against human HEL cells assessed as reduction in cell growth measured after 3 days by coulter counting method
Cytotoxicity against human HEL cells assessed as reduction in cell growth measured after 3 days by coulter counting method
|
[PMID: 35754374]
|
HEL
|
CC50 |
|
Cytotoxicity against HEL cells after 3 days
Cytotoxicity against HEL cells after 3 days
|
[PMID: 17622128]
|
HEL
|
EC50 |
≥ 212 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay
Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay
|
[PMID: 22858222]
|
HEL
|
IC50 |
0.04 μg/mL
Compound: L-BVDU
|
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.
|
[PMID: 7877148]
|
HEL
|
EC50 |
0.08 μM
Compound: Acyclovir
|
Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
|
[PMID: 23603046]
|
HEL
|
EC50 |
0.08 μM
Compound: Acyclovir
|
Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
|
[PMID: 23603046]
|
HEL
|
EC50 |
0.1 μM
Compound: Acyclovir
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days
|
[PMID: 24690527]
|
HEL
|
IC50 |
0.15 μg/mL
Compound: L-BVDU
|
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%
Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%
|
[PMID: 7877148]
|
HEL
|
IC50 |
|
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+OKA strain
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+OKA strain
|
[PMID: 10411487]
|
HEL
|
EC50 |
0.2 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase-positive Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days
Antiviral activity against thymidine kinase-positive Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days
|
[PMID: 24690527]
|
HEL
|
EC50 |
0.2 μM
Compound: Acyclovir
|
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
|
[PMID: 22459876]
|
HEL
|
EC50 |
0.38 μM
Compound: Acyclovir
|
Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay
Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay
|
[PMID: 22858222]
|
HEL
|
EC50 |
0.4 μM
Compound: Acyclovir
|
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days
|
[PMID: 22459876]
|
HEL
|
EC50 |
0.4 μM
Compound: Acyclovir
|
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
|
[PMID: 21696963]
|
HEL
|
EC50 |
0.4 μM
Compound: Acyclovir
|
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
|
[PMID: 21696963]
|
HEL
|
EC50 |
0.49 μM
Compound: Acyclovir
|
Antiviral activity against VSV OKA expressing thymidine kinase infected in HEL cells assessed as reduction of virus plaque formation after 4 days
Antiviral activity against VSV OKA expressing thymidine kinase infected in HEL cells assessed as reduction of virus plaque formation after 4 days
|
[PMID: 22459876]
|
HEL
|
EC50 |
0.53 μM
Compound: Acyclovir
|
Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay
Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay
|
[PMID: 22858222]
|
HEL
|
EC50 |
0.7 μM
Compound: Acyclovir
|
Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
|
[PMID: 32214762]
|
HEL
|
IC50 |
|
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+YS strain
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK+YS strain
|
[PMID: 10411487]
|
HEL
|
EC50 |
0.9 μM
Compound: acyclovir
|
Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain OKA virus plaque formation by 50% in HEL cell culture
Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain OKA virus plaque formation by 50% in HEL cell culture
|
[PMID: 15481985]
|
HEL
|
EC50 |
|
Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay
|
[PMID: 32214762]
|
HEL
|
EC50 |
1 μM
Compound: 14, acyclovir
|
Antiviral activity against TK+ VZV YS in HEL cells after 5 days
Antiviral activity against TK+ VZV YS in HEL cells after 5 days
|
[PMID: 18052321]
|
HEL
|
EC50 |
|
Antiviral activity against thymidine kinase-positive VZV OKA in human HEL cells after 7 days
Antiviral activity against thymidine kinase-positive VZV OKA in human HEL cells after 7 days
|
[PMID: 17672445]
|
HEL
|
EC50 |
1 μM
Compound: 5 (Acyclovir)
|
Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls.
Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV TS plaque formation after 5 days in HEL cell cultures compared to untreated controls.
|
[PMID: 11150169]
|
HEL
|
EC50 |
1.3 μM
Compound: acyclovir
|
Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain YS virus plaque formation by 50% in HEL cell culture
Effective concentration required to reduce TK+ (thymidine kinase presence) VZV strain YS virus plaque formation by 50% in HEL cell culture
|
[PMID: 15481985]
|
HEL
|
EC50 |
|
Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days
Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days
|
[PMID: 17622128]
|
HEL
|
EC50 |
1.64 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase positive VZV OKa infected in HEL cells by plaque formation assay
Antiviral activity against thymidine kinase positive VZV OKa infected in HEL cells by plaque formation assay
|
[PMID: 22858222]
|
HEL
|
EC50 |
|
Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
|
[PMID: 19339082]
|
HEL
|
EC50 |
111 μM
Compound: Acyclovir
|
Effective concentration required to reduce Varicella-Zoster virus 07/1(TK-) plaque formation after 5 days in HEL fibroblast cell line
Effective concentration required to reduce Varicella-Zoster virus 07/1(TK-) plaque formation after 5 days in HEL fibroblast cell line
|
[PMID: 15801851]
|
HEL
|
IC50 |
|
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) YS/R strain
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) YS/R strain
|
[PMID: 10411487]
|
HEL
|
EC50 |
125 μM
Compound: 14, acyclovir
|
Antiviral activity against TK- VZV YS in HEL cells after 5 days
Antiviral activity against TK- VZV YS in HEL cells after 5 days
|
[PMID: 18052321]
|
HEL
|
EC50 |
125 μM
Compound: 5 (Acyclovir)
|
Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.
Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-YS-R ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.
|
[PMID: 11150169]
|
HEL
|
CC50 |
1338 μM
Compound: Acyclovir
|
Cytotoxicity against human HEL cells after 3 days by coulter counter
Cytotoxicity against human HEL cells after 3 days by coulter counter
|
[PMID: 21745746]
|
HEL
|
CC50 |
134 μM
Compound: Acyclovir
|
Cytotoxicity against HEL after 3 days
Cytotoxicity against HEL after 3 days
|
[PMID: 23047229]
|
HEL
|
CC50 |
137 μg/mL
Compound: aciclovir
|
Cytotoxicity against HEL cells assessed as reduction of growth after 3 days
Cytotoxicity against HEL cells assessed as reduction of growth after 3 days
|
[PMID: 18835175]
|
HEL
|
EC50 |
140 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase-deficient Varicella zoster virus 07-1 infected in HEL cells assessed as reduction in viral plaque formation after 5 days
Antiviral activity against thymidine kinase-deficient Varicella zoster virus 07-1 infected in HEL cells assessed as reduction in viral plaque formation after 5 days
|
[PMID: 24690527]
|
HEL
|
CC50 |
1421 μM
Compound: Acyclovir
|
Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter
Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter
|
[PMID: 21565516]
|
HEL
|
IC50 |
15 μg/mL
Compound: L-BVDU
|
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.
|
[PMID: 7877148]
|
HEL
|
EC50 |
15 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days
Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days
|
[PMID: 23047229]
|
HEL
|
EC50 |
17 μM
Compound: Acyclovir
|
Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
|
[PMID: 15801851]
|
HEL
|
IC50 |
|
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) 07/1 strain
The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against Varicella zoster TK-(deficient) 07/1 strain
|
[PMID: 10411487]
|
HEL
|
EC50 |
|
Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
|
[PMID: 19339082]
|
HEL
|
CC50 |
191 μM
Compound: Acyclovir
|
Cytotoxicity against HEL cells assessed as growth inhibition after 3 days by coulter counter method
Cytotoxicity against HEL cells assessed as growth inhibition after 3 days by coulter counter method
|
[PMID: 27639368]
|
HEL
|
EC50 |
|
Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days
Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days
|
[PMID: 19339082]
|
HEL
|
EC50 |
|
Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation after 5 days
Antiviral activity against TK+ VZV OKA infected HEL cells assessed as reduction in virus plaque formation after 5 days
|
[PMID: 18614365]
|
HEL
|
EC50 |
2.6 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase-positive Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation after 5 days
Antiviral activity against thymidine kinase-positive Varicella zoster virus Oka infected in HEL cells assessed as reduction in viral plaque formation after 5 days
|
[PMID: 24690527]
|
HEL
|
EC50 |
2.7 μM
Compound: Acyclovir
|
Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 3 days
Antiviral activity against VZV OKA expressing thymidine kinase infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 3 days
|
[PMID: 23047229]
|
HEL
|
EC50 |
2.84 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase positive VZV YS infected in HEL cells by plaque formation assay
Antiviral activity against thymidine kinase positive VZV YS infected in HEL cells by plaque formation assay
|
[PMID: 22858222]
|
HEL
|
EC50 |
|
Antiviral activity against TK+ VZV YS infected HEL cells assessed as reduction in virus plaque formation after 5 days
Antiviral activity against TK+ VZV YS infected HEL cells assessed as reduction in virus plaque formation after 5 days
|
[PMID: 18614365]
|
HEL
|
EC50 |
2.9 μM
Compound: 14, acyclovir
|
Antiviral activity against TK+ VZV OKA in HEL cells after 5 days
Antiviral activity against TK+ VZV OKA in HEL cells after 5 days
|
[PMID: 18052321]
|
HEL
|
EC50 |
2.9 μM
Compound: 5 (Acyclovir)
|
Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls.
Evaluated for the anti-VZV activity, the concentration of compounds in uM required to reduce VZV OKA Plaque formation after 5 days in HEL cell cultures compared to untreated controls.
|
[PMID: 11150169]
|
HEL
|
IC50 |
20 μg/mL
Compound: L-BVDU
|
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.
Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.
|
[PMID: 7877148]
|
HEL
|
EC50 |
20 μM
Compound: Acyclovir
|
Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection
|
[PMID: 15801851]
|
HEL
|
CC50 |
212 μg/mL
Compound: acyclovir
|
Cytotoxicity against HEL cells assessed as cell growth after 3 days
Cytotoxicity against HEL cells assessed as cell growth after 3 days
|
[PMID: 17948980]
|
HEL
|
EC50 |
|
Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days
Antiviral activity against thymidine kinase deficient VZV YS/R in HEL cells assessed as reduction of virus plaque formation after 5 days
|
[PMID: 17622128]
|
HEL
|
EC50 |
24 μM
Compound: acyclovir
|
Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain 07/1 virus plaque formation by 50% in HEL cell culture
Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain 07/1 virus plaque formation by 50% in HEL cell culture
|
[PMID: 15481985]
|
HEL
|
EC50 |
26.6 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase-deficient VSV 07-1 infected in HEL cells assessed as reduction of virus plaque formation after 4 days
Antiviral activity against thymidine kinase-deficient VSV 07-1 infected in HEL cells assessed as reduction of virus plaque formation after 4 days
|
[PMID: 22459876]
|
HEL
|
EC50 |
27 μM
Compound: acyclovir
|
Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain YS/R virus plaque formation by 50% in HEL cell culture
Effective concentration required to reduce TK+ (thymidine kinase deficient) VZV strain YS/R virus plaque formation by 50% in HEL cell culture
|
[PMID: 15481985]
|
HEL
|
EC50 |
29 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis
|
[PMID: 23603046]
|
HEL
|
IC50 |
|
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.
|
[PMID: 7877148]
|
HEL
|
EC50 |
3.3 μM
Compound: Acyclovir
|
Antiviral activity against VZV OKA expressing thymidine kinase infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days
Antiviral activity against VZV OKA expressing thymidine kinase infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days
|
[PMID: 21128666]
|
HEL
|
IC50 |
|
Tested for inhibitory activity against Varicella zoster virus(VZV) by plaque reduction assay using HEL cells
Tested for inhibitory activity against Varicella zoster virus(VZV) by plaque reduction assay using HEL cells
|
[PMID: 10649983]
|
HEL
|
EC50 |
32 μM
Compound: acyclovir
|
Antiviral activity against thymidine kinase deficient VZV 07/1 in human HEL cells after 7 days
Antiviral activity against thymidine kinase deficient VZV 07/1 in human HEL cells after 7 days
|
[PMID: 17672445]
|
HEL
|
EC50 |
|
Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days
Antiviral activity against thymidine kinase deficient VZV 07/1 in HEL cells assessed as reduction of virus plaque formation after 5 days
|
[PMID: 17622128]
|
HEL
|
EC50 |
37 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase negative VZV YS/R infected in HEL cells by plaque formation assay
Antiviral activity against thymidine kinase negative VZV YS/R infected in HEL cells by plaque formation assay
|
[PMID: 22858222]
|
HEL
|
EC50 |
|
Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days
Antiviral activity against TK+ VZV OKA in HEL cells assessed as reduction of virus plaque formation after 5 days
|
[PMID: 17622128]
|
HEL
|
EC50 |
4.09 μM
Compound: Acyclovir, ACV
|
Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in YS strain HEL cell lines
Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in YS strain HEL cell lines
|
[PMID: 11495586]
|
HEL
|
EC50 |
4.53 μM
Compound: Acyclovir, ACV
|
Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in OKA strain HEL cell lines
Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in OKA strain HEL cell lines
|
[PMID: 11495586]
|
HEL
|
EC50 |
41 μM
Compound: Acyclovir, ACV
|
Effective concentration required to inhibit Tyrosine kinase deficient (TK-) Varicella-Zoster virus-induced cytopathicity by 50% in 07/01 strain HEL cell lines
Effective concentration required to inhibit Tyrosine kinase deficient (TK-) Varicella-Zoster virus-induced cytopathicity by 50% in 07/01 strain HEL cell lines
|
[PMID: 11495586]
|
HEL
|
EC50 |
42.7 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in plaque formation measured after 5 days
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07-1 infected in human HEL cells assessed as reduction in plaque formation measured after 5 days
|
[PMID: 32676147]
|
HEL
|
CC50 |
424 μM
Compound: Acyclovir
|
Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis
Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis
|
[PMID: 33479570]
|
HEL
|
EC50 |
|
Antiviral activity against thymidine kinase deficient VZV YS/R infected HEL cells assessed as reduction in virus plaque formation after 5 days
Antiviral activity against thymidine kinase deficient VZV YS/R infected HEL cells assessed as reduction in virus plaque formation after 5 days
|
[PMID: 18614365]
|
HEL
|
CC50 |
440 μM
Compound: Acyclovir
|
Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 to 5 days by Coulter counting analysis
Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 to 5 days by Coulter counting analysis
|
[PMID: 24690527]
|
HEL
|
EC50 |
|
Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection
|
[PMID: 19339082]
|
HEL
|
CC50 |
470 μM
Compound: Acyclovir
|
Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter
Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter
|
[PMID: 22578783]
|
HEL
|
IC50 |
|
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.
Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.
|
[PMID: 7877148]
|
HEL
|
EC50 |
50 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 B-2006 infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days
Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 B-2006 infected in HEL cells assessed as reduction in virus-induced cytopathicity after 3 days
|
[PMID: 24690527]
|
HEL
|
EC50 |
50 μM
Compound: Acyclovir
|
Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis
|
[PMID: 21696963]
|
HEL
|
EC50 |
54 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase negative VZV 07/01 infected in HEL cells by plaque formation assay
Antiviral activity against thymidine kinase negative VZV 07/01 infected in HEL cells by plaque formation assay
|
[PMID: 22858222]
|
HEL
|
EC50 |
|
Antiviral activity against thymidine kinase deficient VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation after 5 days
Antiviral activity against thymidine kinase deficient VZV 07/1 infected HEL cells assessed as reduction in virus plaque formation after 5 days
|
[PMID: 18614365]
|
HEL
|
EC50 |
62 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days
Antiviral activity against thymidine kinase-deficient VZV 07/1 infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 5 days
|
[PMID: 21128666]
|
HEL
|
EC50 |
62.2 μM
Compound: 1a, ACV
|
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days
|
[PMID: 19339082]
|
HEL
|
EC50 |
63 μM
Compound: Acyclovir, ACV
|
Effective concentration required to inhibit Tyrosine kinase deficient (TK-) Varicella-Zoster virus-induced cytopathicity by 50% in YS/R strain HEL cell lines
Effective concentration required to inhibit Tyrosine kinase deficient (TK-) Varicella-Zoster virus-induced cytopathicity by 50% in YS/R strain HEL cell lines
|
[PMID: 11495586]
|
HEL
|
CC50 |
649 μM
Compound: acyclovir
|
Cytotoxicity against HEL cells assessed as cell growth after 7 days
Cytotoxicity against HEL cells assessed as cell growth after 7 days
|
[PMID: 17539622]
|
HEL
|
EC50 |
7.06 μM
Compound: Acyclovir
|
Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in plaque formation measured after 5 days
Antiviral activity against thymidine kinase positive Varicella zoster virus OKA infected in human HEL cells assessed as reduction in plaque formation measured after 5 days
|
[PMID: 32676147]
|
HEL
|
EC50 |
7.1 μM
Compound: Acyclovir
|
Effective concentration required to reduce Varicella-Zoster virus OKA(TK) plaque formation after 5 days in HEL fibroblast cell line
Effective concentration required to reduce Varicella-Zoster virus OKA(TK) plaque formation after 5 days in HEL fibroblast cell line
|
[PMID: 15801851]
|
HEL
|
CC50 |
733 μM
Compound: ACV, acyclovir
|
Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days
Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days
|
[PMID: 19226140]
|
HEL
|
EC50 |
74 μM
Compound: 14, acyclovir
|
Antiviral activity against TK- VZV 07 in HEL cells after 5 days
Antiviral activity against TK- VZV 07 in HEL cells after 5 days
|
[PMID: 18052321]
|
HEL
|
EC50 |
74 μM
Compound: 5 (Acyclovir)
|
Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.
Evaluated for the anti-VZV, the concentration of compounds in uM required to reduce VZVTK-07 ( thymidine kinase-deficient strain ) plaque formation after 5 days in HEL cell cultures compared to untreated controls.
|
[PMID: 11150169]
|
HEL
|
CC50 |
|
Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days
Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days
|
[PMID: 19339082]
|
HEL
|
CC50 |
|
Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method
Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method
|
[PMID: 28829913]
|
HEL
|
CC50 |
918 μM
Compound: Acyclovir
|
Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay
Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay
|
[PMID: 22858222]
|
HEL 299
|
CC50 |
|
Cytotoxicity against human HEL299 cells after 3 days by MTT assay
Cytotoxicity against human HEL299 cells after 3 days by MTT assay
|
[PMID: 26460883]
|
HeLa
|
CC50 |
> 400 μM
Compound: Aciclovir
|
Cytotoxic concentration required to inhibit Hel cell growth by using DMSO as solvent
Cytotoxic concentration required to inhibit Hel cell growth by using DMSO as solvent
|
[PMID: 15993062]
|
HeLa
|
CC50 |
541 μM
Compound: Acyclovir
|
Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay
Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay
|
[PMID: 22459876]
|
HEp-2
|
IC50 |
> 10 μg/mL
Compound: acyclovir
|
Cytotoxicity against HSV2 infected human Hep2 cells after 3 days
Cytotoxicity against HSV2 infected human Hep2 cells after 3 days
|
[PMID: 9599250]
|
HEp-2
|
IC50 |
> 67 μg/mL
Compound: acyclovir
|
Cytotoxicity against HSV1 infected human Hep2 cells after 3 days
Cytotoxicity against HSV1 infected human Hep2 cells after 3 days
|
[PMID: 9599250]
|
HEp-2
|
EC50 |
0.26 μg/mL
Compound: acyclovir
|
Antiviral activity against HSV1 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days
Antiviral activity against HSV1 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days
|
[PMID: 9599250]
|
HEp-2
|
EC50 |
2.3 μg/mL
Compound: acyclovir
|
Antiviral activity against HSV2 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days
Antiviral activity against HSV2 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days
|
[PMID: 9599250]
|
HepG2 2.2.15
|
IC50 |
> 1000 μM
Compound: ACV, Acyclovir
|
Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 6 days by ELISA
Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 6 days by ELISA
|
[PMID: 23369536]
|
HepG2 2.2.15
|
IC50 |
> 1000 μM
Compound: ACV, Acyclovir
|
Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 6 days by ELISA
Antiviral activity against Hepatitis B virus transfected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 6 days by ELISA
|
[PMID: 23369536]
|
HepG2 2.2.15
|
CC50 |
630 μM
Compound: ACV, Acyclovir
|
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in number of viable cells after 3 days by MTT assay
Cytotoxicity against human HepG2.2.15 cells assessed as reduction in number of viable cells after 3 days by MTT assay
|
[PMID: 23369536]
|
HFF
|
CC50 |
> 100 μM
Compound: Acyclovir
|
Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay
Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay
|
[PMID: 20403696]
|
HFF
|
CC50 |
> 100 μM
Compound: Acyclovir
|
Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay
Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay
|
[PMID: 18595689]
|
HFF
|
CC50 |
|
Cytotoxicity against human HFF cells infected with Varicella-zoster virus Ellen assessed as viable cells by neutral red uptake assay
Cytotoxicity against human HFF cells infected with Varicella-zoster virus Ellen assessed as viable cells by neutral red uptake assay
|
[PMID: 21376429]
|
HFF
|
CC50 |
> 100 μM
Compound: acyclovir
|
Cytotoxicity against HFF cells after 3 days
Cytotoxicity against HFF cells after 3 days
|
[PMID: 17434304]
|
HFF
|
IC50 |
> 100 μM
Compound: Acyclovir (ACV)
|
Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection.
Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection.
|
[PMID: 8784444]
|
HFF
|
CC50 |
> 150 μM
Compound: Acyclovir
|
Cytotoxicity against human HFF cells infected with VZV Ellen virus assessed as reduction in cell viability by cell titer-glo assay
Cytotoxicity against human HFF cells infected with VZV Ellen virus assessed as reduction in cell viability by cell titer-glo assay
|
[PMID: 35754374]
|
HFF
|
IC50 |
> 20 μM
Compound: acyclovir
|
Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO
Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO
|
[PMID: 16134946]
|
HFF
|
IC50 |
> 20000 nM
Compound: acyclovir
|
Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay
Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay
|
[PMID: 17434304]
|
HFF
|
CC50 |
> 300 μM
Compound: Acyclovir
|
Cytotoxicity in HFF cells incubated for 7 days by CellTiter-Glo assay
Cytotoxicity in HFF cells incubated for 7 days by CellTiter-Glo assay
|
[PMID: 27933957]
|
HFF
|
CC50 |
> 300 μM
Compound: Acyclovir
|
Cytotoxicity against HFF by neutral red uptake assay
Cytotoxicity against HFF by neutral red uptake assay
|
[PMID: 19410465]
|
HFF
|
CC50 |
|
Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining
Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining
|
[PMID: 22607883]
|
HFF
|
IC50 |
|
Antiproliferative activity against HFF after 3 days by Coulter counting analysis
Antiproliferative activity against HFF after 3 days by Coulter counting analysis
|
[PMID: 19770274]
|
HFF
|
CC50 |
|
Cytotoxicity against HFF after 3 days by MTS assay
Cytotoxicity against HFF after 3 days by MTS assay
|
[PMID: 19770274]
|
HFF
|
EC50 |
> 444 μM
Compound: ACV, acyclovir
|
Antiviral activity against TK- HSV1 DM2.1 in HFF cells after 72 hrs by plaque reduction assay
Antiviral activity against TK- HSV1 DM2.1 in HFF cells after 72 hrs by plaque reduction assay
|
[PMID: 17325220]
|
HFF
|
EC50 |
> 444 μM
Compound: ACV, acyclovir
|
Antiviral activity against TK- HSV2 AG3 in HFF cells after 72 hrs by plaque reduction assay
Antiviral activity against TK- HSV2 AG3 in HFF cells after 72 hrs by plaque reduction assay
|
[PMID: 17325220]
|
HFF
|
EC50 |
0.03 μM
Compound: acyclovir
|
Inhibition of VZV replication in HFF cells by cytopathic effect assay
Inhibition of VZV replication in HFF cells by cytopathic effect assay
|
[PMID: 17004726]
|
HFF
|
IC50 |
|
Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay
Antiviral activity against HSV1 KOS infected in HFF cells incubated for 3 days by plaque reduction assay
|
[PMID: 21812420]
|
HFF
|
EC50 |
|
Antiviral activity against Varicella-zoster virus Ellen infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay
Antiviral activity against Varicella-zoster virus Ellen infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay
|
[PMID: 21376429]
|
HFF
|
EC50 |
1.1 μM
Compound: Acyclovir
|
Concentration for HSV-1 plaque reduction (VPR) by 50% in HFF cells
Concentration for HSV-1 plaque reduction (VPR) by 50% in HFF cells
|
[PMID: 14584954]
|
HFF
|
EC50 |
1.3 μM
Compound: ACV, acyclovir
|
Antiviral activity against TK+ HSV1 E377 in HFF cells after 72 hrs by plaque reduction assay
Antiviral activity against TK+ HSV1 E377 in HFF cells after 72 hrs by plaque reduction assay
|
[PMID: 17325220]
|
HFF
|
EC50 |
1.6 μM
Compound: acyclovir
|
Inhibition of VZV replication in HFF cells by CPE assay
Inhibition of VZV replication in HFF cells by CPE assay
|
[PMID: 15615545]
|
HFF
|
EC50 |
1.68 μM
Compound: Acyclovir
|
Concentration for HSV-2 plaque reduction (VPR) by 50% in HFF cells
Concentration for HSV-2 plaque reduction (VPR) by 50% in HFF cells
|
[PMID: 14584954]
|
HFF
|
IC50 |
|
Antiviral activity against VZV infected in human HFF cells assessed as reduction in cytopathic effect after 7 days by crystal violet staining
Antiviral activity against VZV infected in human HFF cells assessed as reduction in cytopathic effect after 7 days by crystal violet staining
|
[PMID: 22607883]
|
HFF
|
EC50 |
10.21 μM
Compound: Acyclovir
|
Inhibitory concentration required to reduce HSV-2 induced cytopathogenic effect (CPE) by 50 % in HFF cells
Inhibitory concentration required to reduce HSV-2 induced cytopathogenic effect (CPE) by 50 % in HFF cells
|
[PMID: 14584954]
|
HFF
|
EC50 |
2.22 μM
Compound: Acyclovir
|
Inhibitory concentration required to reduce HSV-1 induced cytopathogenic effect (CPE) by 50 % in HFF cells
Inhibitory concentration required to reduce HSV-1 induced cytopathogenic effect (CPE) by 50 % in HFF cells
|
[PMID: 14584954]
|
HFF
|
IC50 |
2.7 μg/mL
Compound: 1a(ACV)
|
Inhibitory activity against DM625 strain of zoster virus(VZV) by plaque reduction assay in HFF cells
Inhibitory activity against DM625 strain of zoster virus(VZV) by plaque reduction assay in HFF cells
|
[PMID: 9548818]
|
HFF
|
IC50 |
|
Antiviral activity against HSV-2 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining
Antiviral activity against HSV-2 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining
|
[PMID: 22607883]
|
HFF
|
IC50 |
|
Antiviral activity against HSV-1 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining
Antiviral activity against HSV-1 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining
|
[PMID: 22607883]
|
HFF
|
IC50 |
20000 nM
Compound: Acyclovir
|
Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay
Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay
|
[PMID: 20167488]
|
HFF
|
EC50 |
3.1 μM
Compound: ACV, acyclovir
|
Antiviral activity against TK- HSV2 MS in HFF cells after 72 hrs by plaque reduction assay
Antiviral activity against TK- HSV2 MS in HFF cells after 72 hrs by plaque reduction assay
|
[PMID: 17325220]
|
HFF
|
IC50 |
8.1 μM
Compound: acyclovir
|
Antiviral activity against Varicella-Zoster virus (Webster strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed [nd = not
Antiviral activity against Varicella-Zoster virus (Webster strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed [nd = not
|
[PMID: 16134946]
|
HFF
|
EC50 |
8.5 μM
Compound: ACV, acyclovir
|
Antiviral activity against Varicella-Zoster virus Ellen in HFF cells after 10 days by plaque reduction assay
Antiviral activity against Varicella-Zoster virus Ellen in HFF cells after 10 days by plaque reduction assay
|
[PMID: 17325220]
|
HFF
|
IC50 |
8100 nM
Compound: Acyclovir
|
Antiviral activity against Varicella zoster virus infected in HFF cells by plaque reduction assay
Antiviral activity against Varicella zoster virus infected in HFF cells by plaque reduction assay
|
[PMID: 20167488]
|
HFF
|
IC50 |
8100 nM
Compound: acyclovir
|
Antiviral activity against VZV Webster in HFF cells by plaque reduction assay
Antiviral activity against VZV Webster in HFF cells by plaque reduction assay
|
[PMID: 17434304]
|
Huh-7
|
EC50 |
> 1000 μM
Compound: Acyclovir
|
Antiviral activity against MERS-CoV EMC/2012 infected in human HuH7 cells assessed as inhibition of virus-induced cytopathic effect after 2 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay
Antiviral activity against MERS-CoV EMC/2012 infected in human HuH7 cells assessed as inhibition of virus-induced cytopathic effect after 2 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay
|
[PMID: 26048809]
|
Huh-7
|
CC50 |
> 1000 μM
Compound: Acyclovir
|
Cytotoxicity against mock-infected human HuH7 cells assessed as inhibition of cell survival after 2 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay
Cytotoxicity against mock-infected human HuH7 cells assessed as inhibition of cell survival after 2 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay
|
[PMID: 26048809]
|
KB
|
IC50 |
> 100 μM
Compound: Acyclovir
|
Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB).
Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB).
|
[PMID: 1310744]
|
MRC5
|
IC50 |
13 μM
Compound: Acyclovir
|
Antiviral activity against Varicella zoster virus Ellen infected in human MRC5 cells assessed as inhibition of viral replication by viral reduction plaque assay
Antiviral activity against Varicella zoster virus Ellen infected in human MRC5 cells assessed as inhibition of viral replication by viral reduction plaque assay
|
[PMID: 23219702]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay
Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay
|
[PMID: 26443549]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay
Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay
|
[PMID: 25082514]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
|
[PMID: 20359898]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
|
[PMID: 19482481]
|
MT4
|
EC50 |
> 250 μM
Compound: 10, ACV
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as p24 production after 3 days by microscopic analysis
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as p24 production after 3 days by microscopic analysis
|
[PMID: 24177359]
|
MT4
|
EC50 |
> 250 μM
Compound: 1, ACV
|
Antiviral activity against HIV1 3B/Lai infected in human MT4 cells assessed as suppression of p24 production after 3 days
Antiviral activity against HIV1 3B/Lai infected in human MT4 cells assessed as suppression of p24 production after 3 days
|
[PMID: 19645484]
|
MT4
|
CC50 |
> 250 μM
Compound: 10, ACV
|
Cytotoxicity against human MT4 cells assessed as cell viability by propidium iodide staining-based cell counting analysis
Cytotoxicity against human MT4 cells assessed as cell viability by propidium iodide staining-based cell counting analysis
|
[PMID: 24177359]
|
NC-37
|
CC50 |
> 100 μg/mL
Compound: Acyclovir
|
Cytotoxic concentration required to inhibit NC-37 cells by 50%
Cytotoxic concentration required to inhibit NC-37 cells by 50%
|
10.1016/S0960-894X(01)80146-3
|
Raji
|
ED50 |
3.8 μg/mL
Compound: Acyclovir
|
Tested for the inhibition of diffuse early antigen production assayed by immunofluorescent monoclonal antibody.
Tested for the inhibition of diffuse early antigen production assayed by immunofluorescent monoclonal antibody.
|
[PMID: 2329551]
|
Vero
|
CC50 |
|
Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay
Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay
|
[PMID: 12444692]
|
Vero
|
IC50 |
> 10 μM
Compound: acyclovir
|
Antiviral activity against herpes simplex virus type 1 KOS (PAAr5) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
Antiviral activity against herpes simplex virus type 1 KOS (PAAr5) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
|
[PMID: 16134946]
|
Vero
|
IC50 |
> 10 μM
Compound: acyclovir
|
Antiviral activity against herpes simplex virus type 1 KOS (PFAr2) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
Antiviral activity against herpes simplex virus type 1 KOS (PFAr2) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
|
[PMID: 16134946]
|
Vero
|
IC50 |
> 10 μM
Compound: acyclovir
|
Antiviral activity against herpes simplex virus type 1 Patton (BWr) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
Antiviral activity against herpes simplex virus type 1 Patton (BWr) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
|
[PMID: 16134946]
|
Vero
|
IC50 |
> 10 μM
Compound: acyclovir
|
Antiviral activity against herpes simplex virus type 1 KOS (AraAr13) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
Antiviral activity against herpes simplex virus type 1 KOS (AraAr13) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
|
[PMID: 16134946]
|
Vero
|
IC50 |
> 100 μg/mL
Compound: Acyclovir
|
Cytotoxicity against african green monkey Vero cells by MTT assay
Cytotoxicity against african green monkey Vero cells by MTT assay
|
[PMID: 9214738]
|
Vero
|
CC50 |
> 100 μg/mL
Compound: 1b (Acyclovir)
|
Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay
Compound was evaluated for cytotoxicity against stationary Vero cells using MTT assay
|
[PMID: 11677126]
|
Vero
|
CC50 |
> 100 μM
Compound: Acyclovir
|
Cytotoxicity against african green monkey Vero cells after 69 hrs by Alamar blue assay
Cytotoxicity against african green monkey Vero cells after 69 hrs by Alamar blue assay
|
[PMID: 17981031]
|
Vero
|
CC50 |
|
Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining
Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by crystal violet staining
|
[PMID: 22047799]
|
Vero
|
CC50 |
|
Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining
Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining
|
[PMID: 19482481]
|
Vero
|
CC50 |
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTS assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTS assay
|
[PMID: 35635945]
|
Vero
|
CC50 |
> 100 μM
Compound: Acyclovir
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 3 days by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 3 days by MTT assay
|
[PMID: 34766503]
|
Vero
|
CC50 |
> 100 μM
Compound: Acycloguanosine
|
Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay
Cytotoxicity against african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay
|
[PMID: 22513121]
|
Vero
|
EC50 |
|
Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay
Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay
|
[PMID: 25082514]
|
Vero
|
EC50 |
|
Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay
Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay
|
[PMID: 25082514]
|
Vero
|
EC50 |
|
Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay
Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay
|
[PMID: 20359898]
|
Vero
|
EC50 |
|
Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay
Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay
|
[PMID: 25082514]
|
Vero
|
EC50 |
|
Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay
Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay
|
[PMID: 25082514]
|
Vero
|
EC50 |
|
Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay
Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay
|
[PMID: 20359898]
|
Vero
|
EC50 |
|
Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay
Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay
|
[PMID: 20359898]
|
Vero
|
EC50 |
|
Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay
Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay
|
[PMID: 25082514]
|
Vero
|
EC50 |
|
Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay
Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay
|
[PMID: 20359898]
|
Vero
|
CC50 |
> 1000 μM
Compound: Acyclovir
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay
|
[PMID: 28129981]
|
Vero
|
EC50 |
> 1000 μM
Compound: Acyclovir
|
Antiviral activity against MERS-CoV EMC/2012 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay
Antiviral activity against MERS-CoV EMC/2012 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay
|
[PMID: 26048809]
|
Vero
|
CC50 |
> 1000 μM
Compound: Acyclovir
|
Cytotoxicity against mock-infected African green monkey Vero cells assessed as inhibition of cell survival after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay
Cytotoxicity against mock-infected African green monkey Vero cells assessed as inhibition of cell survival after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay
|
[PMID: 26048809]
|
Vero
|
ED50 |
|
Concentration of compound required to reduce by 50% the number of african swine fever virus (ASFV) plaques in vero cells
Concentration of compound required to reduce by 50% the number of african swine fever virus (ASFV) plaques in vero cells
|
[PMID: 1548681]
|
Vero
|
IC50 |
|
Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 72 hrs
Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 72 hrs
|
[PMID: 26638041]
|
Vero
|
CC50 |
|
Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 24 hrs by CellTiter-Glo luminescent assay
Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 24 hrs by CellTiter-Glo luminescent assay
|
[PMID: 29099182]
|
Vero
|
CC50 |
|
Cytotoxicity against african green monkey Vero cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells assessed as inhibition of cell viability after 48 hrs by MTT assay
|
[PMID: 22704890]
|
Vero
|
CC50 |
|
Cytotoxicity against african green monkey Vero cells by MTT assay
Cytotoxicity against african green monkey Vero cells by MTT assay
|
[PMID: 21334891]
|
Vero
|
CC50 |
> 200 μM
Compound: Acyclovir
|
Cytotoxicity against african green monkey Vero cells after 3 days by neutral red dye method
Cytotoxicity against african green monkey Vero cells after 3 days by neutral red dye method
|
[PMID: 23141915]
|
Vero
|
CC50 |
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 30798081]
|
Vero
|
CC50 |
> 2000 μM
Compound: 1, Acyclovir, ACV
|
Cytotoxicity against african green monkey Vero E6 cells after 72 hrs by trypan blue staining
Cytotoxicity against african green monkey Vero E6 cells after 72 hrs by trypan blue staining
|
[PMID: 22954898]
|
Vero
|
CC50 |
|
Cytotoxicity against african green monkey Vero cells by MTT assay
Cytotoxicity against african green monkey Vero cells by MTT assay
|
[PMID: 23419738]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 isolate 1 harboring C6G N23S K36E L42P G240E A265T and A207P mutations in thymidine kinase and S33G, A330R, N425T, V905M mutations in DNA polymerase infected in african green monkey Vero cells by plaque re
Antiviral activity against Herpes simplex virus 1 isolate 1 harboring C6G N23S K36E L42P G240E A265T and A207P mutations in thymidine kinase and S33G, A330R, N425T, V905M mutations in DNA polymerase infected in african green monkey Vero cells by plaque re
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 isolate 9 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 228 mutations in thymidine kinase and S33G, A330R, V905M, A1203T, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by
Antiviral activity against Herpes simplex virus 1 isolate 9 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 228 mutations in thymidine kinase and S33G, A330R, V905M, A1203T, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 isolate 11 harboring N23S, K36E, G251C, A265T, P268T, R176W mutations in thymidine kinase and S33G, A330R, P1124H, T1208A, S724N, V117L, L267M mutations in DNA polymerase infected in african green monkey V
Antiviral activity against Herpes simplex virus 1 isolate 11 harboring N23S, K36E, G251C, A265T, P268T, R176W mutations in thymidine kinase and S33G, A330R, P1124H, T1208A, S724N, V117L, L267M mutations in DNA polymerase infected in african green monkey V
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 isolate 16 harboring D137Stop mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Herpes simplex virus 2 isolate 16 harboring D137Stop mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 isolate 17 harboring G39E, N78D Q222Stop mutations in thymidine kinase and A9T, P15S, L60P, T801P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Herpes simplex virus 2 isolate 17 harboring G39E, N78D Q222Stop mutations in thymidine kinase and A9T, P15S, L60P, T801P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 isolate 19 harboring G39E, +2G 439-440 = Stop 184 mutations in thymidine kinase and A9T, P15S, L60P, del, DGDE683-686 mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduc
Antiviral activity against Herpes simplex virus 2 isolate 19 harboring G39E, +2G 439-440 = Stop 184 mutations in thymidine kinase and A9T, P15S, L60P, del, DGDE683-686 mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduc
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 isolate 20 harboring G39E, -1C 467 = Stop 183 mutations in thymidine kinase and A9T, P15S, L60P, E139K, T801P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction ass
Antiviral activity against Herpes simplex virus 2 isolate 20 harboring G39E, -1C 467 = Stop 183 mutations in thymidine kinase and A9T, P15S, L60P, E139K, T801P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction ass
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 isolate 21 harboring G39E, N78D, L140F, -1C 452 = Stop 183 mutations in thymidine kinase and P15S, L60P, E678G mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction as
Antiviral activity against Herpes simplex virus 2 isolate 21 harboring G39E, N78D, L140F, -1C 452 = Stop 183 mutations in thymidine kinase and P15S, L60P, E678G mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction as
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 isolate 22 harboring G39E, N78D, L140F, +1G 439-440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, E678G, Y823C mutations in DNA polymerase infected in african green monkey Vero cells by pla
Antiviral activity against Herpes simplex virus 2 isolate 22 harboring G39E, N78D, L140F, +1G 439-440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, E678G, Y823C mutations in DNA polymerase infected in african green monkey Vero cells by pla
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 isolate 23 harboring G39E, N78D, L140F, +1G 439-440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, I291V mutations in DNA polymerase infected in african green monkey Vero cells by plaque red
Antiviral activity against Herpes simplex virus 2 isolate 23 harboring G39E, N78D, L140F, +1G 439-440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, I291V mutations in DNA polymerase infected in african green monkey Vero cells by plaque red
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 isolate 24 harboring G39E, -1G 440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, E139K, H837R mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction ass
Antiviral activity against Herpes simplex virus 2 isolate 24 harboring G39E, -1G 440 = Stop 229 mutations in thymidine kinase and A9T, P15S, L60P, E139K, H837R mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction ass
|
[PMID: 20733037]
|
Vero
|
CC50 |
> 500 μg/mL
Compound: acyclovir
|
Cytotoxicity against african green monkey Vero cells after 3 days by MTT reduction assay
Cytotoxicity against african green monkey Vero cells after 3 days by MTT reduction assay
|
[PMID: 16724853]
|
Vero
|
CC50 |
|
Cytotoxicity against african green monkey Vero cells after 2 days
Cytotoxicity against african green monkey Vero cells after 2 days
|
[PMID: 17438061]
|
Vero
|
IC50 |
0.0043 mM
Compound: aciclovir
|
Antiviral activity against HSV1 infected african green monkey Vero cells assessed as reduction of plaque formation after 3 days by using crystal violet stain
Antiviral activity against HSV1 infected african green monkey Vero cells assessed as reduction of plaque formation after 3 days by using crystal violet stain
|
[PMID: 20092288]
|
Vero
|
IC50 |
0.0043 mM
Compound: acyclovir
|
Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days
Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days
|
[PMID: 19422205]
|
Vero
|
ED50 |
|
Concentration of compound required to reduce by 50% the number of herpes simplex virus (HSV-1) plaques in vero cells
Concentration of compound required to reduce by 50% the number of herpes simplex virus (HSV-1) plaques in vero cells
|
[PMID: 1548681]
|
Vero
|
EC50 |
|
Antiviral activity against HSV1 KOS ATCC VR1493 infected in African green monkey Vero cells assessed as reduction in EGFP-positive cells treated at 2 hrs post infection measured 24 hrs post infection by flow cytometric analysis
Antiviral activity against HSV1 KOS ATCC VR1493 infected in African green monkey Vero cells assessed as reduction in EGFP-positive cells treated at 2 hrs post infection measured 24 hrs post infection by flow cytometric analysis
|
[PMID: 26819664]
|
Vero
|
IC50 |
|
The concentration required to inhibit the growth of viral plaques by 50% of control in plaque reduction assay
The concentration required to inhibit the growth of viral plaques by 50% of control in plaque reduction assay
|
[PMID: 2991522]
|
Vero
|
IC50 |
0.2 μg/mL
Compound: Acyclovir
|
Antiviral activity against HSV1 F ATCC VR733 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days
Antiviral activity against HSV1 F ATCC VR733 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days
|
[PMID: 23194476]
|
Vero
|
EC50 |
|
Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique
Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique
|
[PMID: 26638041]
|
Vero
|
EC50 |
0.32 μg/mL
Compound: Acyclovir
|
In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in vero cells by a plaque reduction assay
In vitro evaluation of antiviral activity against HSV-1 (Herpes simplex virus-1) induced cytopathic effect in vero cells by a plaque reduction assay
|
10.1016/0960-894X(95)00395-A
|
Vero
|
IC50 |
|
Antiviral activity against acyclovir-sensitive HSV1 L177 isolate replication in african green monkey Vero cells by plaque reduction assay
Antiviral activity against acyclovir-sensitive HSV1 L177 isolate replication in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19010684]
|
Vero
|
EC50 |
0.39 μg/mL
Compound: Acyclovir
|
In vitro evaluation of antiviral activity against HSV-2 (Herpes simplex virus-2) induced cytopathic effect in vero cells by a plaque reduction assay
In vitro evaluation of antiviral activity against HSV-2 (Herpes simplex virus-2) induced cytopathic effect in vero cells by a plaque reduction assay
|
10.1016/0960-894X(95)00395-A
|
Vero
|
IC50 |
0.39 μM
Compound: ACV, Zovirax
|
Antiviral activity against HSV1 SC16 infected in african green monkey Vero cells by hybrid capture method
Antiviral activity against HSV1 SC16 infected in african green monkey Vero cells by hybrid capture method
|
[PMID: 19700316]
|
Vero
|
IC50 |
|
Antiviral activity against HSV1 SC16 in Vero cells by capture hybrid method
Antiviral activity against HSV1 SC16 in Vero cells by capture hybrid method
|
[PMID: 17368024]
|
Vero
|
EC50 |
0.5 μg/mL
Compound: 1b (Acyclovir)
|
Concentration required to inhibit plaque formation by HSV-1 strain KOS (TK+) in monolayers of vero cells
Concentration required to inhibit plaque formation by HSV-1 strain KOS (TK+) in monolayers of vero cells
|
[PMID: 11677126]
|
Vero
|
EC50 |
0.5 μM
Compound: acyclovir
|
Antiviral activity against Herpes simplex virus (type 1 / strain F) infected in Vero cells assessed as reduction of number of viral plaques after 2 days
Antiviral activity against Herpes simplex virus (type 1 / strain F) infected in Vero cells assessed as reduction of number of viral plaques after 2 days
|
[PMID: 22944333]
|
Vero
|
IC50 |
|
Antiviral activity against acyclovir-sensitive HSV1 K161 isolate replication in african green monkey Vero cells by plaque reduction assay
Antiviral activity against acyclovir-sensitive HSV1 K161 isolate replication in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19010684]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay
Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay
|
[PMID: 26460883]
|
Vero
|
EC50 |
0.76 μM
Compound: Acyclovir
|
Antiviral activity against Herpes simplex virus type 1 infected in Vero cells at 0.001 ID50/cells assessed as protection against virus-induced cytopathic effect after 3 days by neutral red dye method
Antiviral activity against Herpes simplex virus type 1 infected in Vero cells at 0.001 ID50/cells assessed as protection against virus-induced cytopathic effect after 3 days by neutral red dye method
|
[PMID: 23141915]
|
Vero
|
EC50 |
|
Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
|
[PMID: 12444692]
|
Vero
|
IC50 |
0.81 μg/mL
Compound: 1a(ACV)
|
Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells
Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells
|
[PMID: 9548818]
|
Vero
|
IC50 |
|
Antiviral activity against 5 MOI Herpes simplex viruses 1 infected in vero cells after 24 hrs by viral plaque number reduction assay
Antiviral activity against 5 MOI Herpes simplex viruses 1 infected in vero cells after 24 hrs by viral plaque number reduction assay
|
[PMID: 21376603]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay
Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay
|
[PMID: 26460883]
|
Vero
|
EC50 |
|
Antiviral activity against Human herpesvirus 1 infected in Vero cells after 72 hr by plaque reduction assay
Antiviral activity against Human herpesvirus 1 infected in Vero cells after 72 hr by plaque reduction assay
|
10.1007/s00044-007-9035-6
|
Vero
|
EC50 |
|
Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as inhibition of viral replication by plaque reduction assay
Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as inhibition of viral replication by plaque reduction assay
|
[PMID: 21334891]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 infected in African green monkey vero cells assessed as reduction in plaque formation treated 1 hr post viral infection by plaque reduction assay
Antiviral activity against Herpes simplex virus 1 infected in African green monkey vero cells assessed as reduction in plaque formation treated 1 hr post viral infection by plaque reduction assay
|
[PMID: 32089391]
|
Vero
|
EC50 |
|
Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay
Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay
|
[PMID: 25082514]
|
Vero
|
EC50 |
|
Antiviral activity against HSV1 strain F ATCC VR733 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay
Antiviral activity against HSV1 strain F ATCC VR733 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay
|
[PMID: 22704890]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
|
[PMID: 17438061]
|
Vero
|
EC50 |
1.5 μg/mL
Compound: Acyclovir
|
Antiviral activity against Human herpesvirus 1 infected African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 3 days by plaque reduction assay
Antiviral activity against Human herpesvirus 1 infected African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 3 days by plaque reduction assay
|
10.1007/s00044-011-9574-8
|
Vero
|
IC50 |
1.5 μg/mL
Compound: Acyclovir
|
Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells
Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells
|
10.1016/S0960-894X(01)80236-5
|
Vero
|
EC50 |
1.5 μg/mL
Compound: Acyclovir
|
Antiviral activity against HSV2 MS in african green monkey Vero cells by viral cytopathic effect assay
Antiviral activity against HSV2 MS in african green monkey Vero cells by viral cytopathic effect assay
|
[PMID: 9214738]
|
Vero
|
EC50 |
|
Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells after 2 to 3 days by plaque reduction assay
Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells after 2 to 3 days by plaque reduction assay
|
[PMID: 22921079]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 F infected in Vero cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
Antiviral activity against Herpes simplex virus 1 F infected in Vero cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
|
[PMID: 23419738]
|
Vero
|
EC50 |
1.7 μM
Compound: 1, Acyclovir, ACV
|
Antiviral activity against HSV1 L2 infected in Vero E6 cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
Antiviral activity against HSV1 L2 infected in Vero E6 cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
|
[PMID: 22954898]
|
Vero
|
EC50 |
|
Antiviral activity against HSV2 infected in african green monkey Vero cells assessed as inhibition of viral replication by plaque reduction assay
Antiviral activity against HSV2 infected in african green monkey Vero cells assessed as inhibition of viral replication by plaque reduction assay
|
[PMID: 21334891]
|
Vero
|
EC50 |
|
Antiviral activity against HSV-2G ATCC 734 infected in african green monkey Vero cells after 2 to 3 days by plaque reduction assay
Antiviral activity against HSV-2G ATCC 734 infected in african green monkey Vero cells after 2 to 3 days by plaque reduction assay
|
[PMID: 22921079]
|
Vero
|
EC50 |
|
Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay
Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay
|
[PMID: 22704890]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 isolate 8 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 228 mutations in thymidine kinase and A330R, P875S, V905M, P1124H, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by
Antiviral activity against Herpes simplex virus 1 isolate 8 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 228 mutations in thymidine kinase and A330R, P875S, V905M, P1124H, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 isolate 2 harboring C6G, N23S, K36E, R41H, A192V, A265T, L170P mutations in thymidine kinase and S33G, A330R, N425T, V905M, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by
Antiviral activity against Herpes simplex virus 1 isolate 2 harboring C6G, N23S, K36E, R41H, A192V, A265T, L170P mutations in thymidine kinase and S33G, A330R, N425T, V905M, T1208A mutations in DNA polymerase infected in african green monkey Vero cells by
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 isolate 15 harboring R221H mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Herpes simplex virus 2 isolate 15 harboring R221H mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 20733037]
|
Vero
|
CC50 |
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 32089391]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
|
[PMID: 17438061]
|
Vero
|
EC50 |
117.6 μM
Compound: Acyclovir
|
Inhibition of plaque formation in monolayers of HSV-1 KOSSB(TK-) Vero cells by 50%
Inhibition of plaque formation in monolayers of HSV-1 KOSSB(TK-) Vero cells by 50%
|
[PMID: 11585457]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
|
[PMID: 17438061]
|
Vero
|
CC50 |
12.2 x 10 4 ug/mL
Compound: acyclovir
|
Cytotoxicity against african green monkey Vero cells by MTT assay
Cytotoxicity against african green monkey Vero cells by MTT assay
|
[PMID: 11678658]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as reduction in plaque formation pretreated with compound for 1 hr followed by viral infection at 0.01 PFU/cells for 1 hr by plaque reduction assay
Antiviral activity against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as reduction in plaque formation pretreated with compound for 1 hr followed by viral infection at 0.01 PFU/cells for 1 hr by plaque reduction assay
|
[PMID: 32089391]
|
Vero
|
CC50 |
126 μM
Compound: acyclovir
|
Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 17937990]
|
Vero
|
CC50 |
1275 μg/mL
Compound: Acyclovir
|
Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as cell viability after 3 days by Alamar blue assay
Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as cell viability after 3 days by Alamar blue assay
|
10.1007/s00044-011-9574-8
|
Vero
|
CC50 |
|
Cytotoxicity against african green monkey Vero cells after 2 days by MTT assay
Cytotoxicity against african green monkey Vero cells after 2 days by MTT assay
|
[PMID: 22921079]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 isolate 4 harboring N23S, K36E -1C 553 = frameshift mutations in thymidine kinase and S33G, A330R, A899V, L1188F mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction
Antiviral activity against Herpes simplex virus 1 isolate 4 harboring N23S, K36E -1C 553 = frameshift mutations in thymidine kinase and S33G, A330R, A899V, L1188F mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 isolate 5 harboring N23S, K36E, A192V, G251C, A265T, V267L, P268T, -1G 856 = frameshift mutations in thymidine kinase and A330R, V905M, T1208A, H98Y mutations in DNA polymerase infected in african green mo
Antiviral activity against Herpes simplex virus 1 isolate 5 harboring N23S, K36E, A192V, G251C, A265T, V267L, P268T, -1G 856 = frameshift mutations in thymidine kinase and A330R, V905M, T1208A, H98Y mutations in DNA polymerase infected in african green mo
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 isolate 18 harboring A27T, G39E, N78D, -1C 556 = Stop 263, S29A mutations in thymidine kinase and A9T, P15S, L60P, E678G, del, DD676-677 mutations in DNA polymerase infected in african green monkey Vero ce
Antiviral activity against Herpes simplex virus 2 isolate 18 harboring A27T, G39E, N78D, -1C 556 = Stop 263, S29A mutations in thymidine kinase and A9T, P15S, L60P, E678G, del, DD676-677 mutations in DNA polymerase infected in african green monkey Vero ce
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay
Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay
|
[PMID: 26460883]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
EC50 |
|
Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19858259]
|
Vero
|
IC50 |
2 μg/mL
Compound: acyclovir
|
Antiviral activity against HSV1 infected in african green monkey Vero cells after 72 hrs by SRB assay
Antiviral activity against HSV1 infected in african green monkey Vero cells after 72 hrs by SRB assay
|
[PMID: 11277765]
|
Vero
|
EC50 |
|
Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 3 days by MTT assay
Antiviral activity against HSV-1F ATCC 733 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 3 days by MTT assay
|
[PMID: 22921079]
|
Vero
|
IC50 |
2.1 μM
Compound: acyclovir
|
Antiviral activity against herpes simplex virus type 1 (KOS strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed [nd = no
Antiviral activity against herpes simplex virus type 1 (KOS strain) grown on human foreskin fibroblast cells determined by vedduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO until plaque were formed [nd = no
|
[PMID: 16134946]
|
Vero
|
EC50 |
|
Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique
Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique
|
[PMID: 26638041]
|
Vero
|
EC50 |
2.2 μM
Compound: Acyclovir
|
Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50%
Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50%
|
[PMID: 11585457]
|
Vero
|
EC50 |
|
Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
|
[PMID: 12444692]
|
Vero
|
IC50 |
2.4 μM
Compound: acyclovir
|
Antiviral activity against herpes simplex virus type 2 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
Antiviral activity against herpes simplex virus type 2 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
|
[PMID: 16134946]
|
Vero
|
EC50 |
2.6 μM
Compound: Acyclovir
|
Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of VZV Ellen Vero cells by 50%
Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of VZV Ellen Vero cells by 50%
|
[PMID: 11585457]
|
Vero
|
EC50 |
|
Antiviral activity against HSV1 infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay
Antiviral activity against HSV1 infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay
|
[PMID: 25913116]
|
Vero
|
IC50 |
2.8 μM
Compound: acyclovir
|
Antiviral activity against herpes simplex virus type 2 (V826A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
Antiviral activity against herpes simplex virus type 2 (V826A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
|
[PMID: 16134946]
|
Vero
|
IC50 |
2100 nM
Compound: acyclovir
|
Antiviral activity against HSV1 KOS in Vero cells by plaque reduction assay
Antiviral activity against HSV1 KOS in Vero cells by plaque reduction assay
|
[PMID: 17434304]
|
Vero
|
EC50 |
22 μM
Compound: Acyclovir
|
Antiviral activity against Herpes simplex virus type 1 infected in Vero cells at 0.01 ID50/cells assessed as protection against virus-induced cytopathic effect after 3 days by neutral red dye method
Antiviral activity against Herpes simplex virus type 1 infected in Vero cells at 0.01 ID50/cells assessed as protection against virus-induced cytopathic effect after 3 days by neutral red dye method
|
[PMID: 23141915]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 isolate 10 harboring N23S, K36E, R89Q, A265T C336Y mutations in thymidine kinase and S33G, A330R, V905M mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Herpes simplex virus 1 isolate 10 harboring N23S, K36E, R89Q, A265T C336Y mutations in thymidine kinase and S33G, A330R, V905M mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 isolate 14 harboring G39E, N78D, M70R mutations in thymidine kinase and A724V mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Herpes simplex virus 2 isolate 14 harboring G39E, N78D, M70R mutations in thymidine kinase and A724V mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 isolate 6 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 225 mutations in thymidine kinase and S33G, A330R, A646T, S1123L, P1124H, T1208A, R1229I mutations in DNA polymerase infected in african green monke
Antiviral activity against Herpes simplex virus 1 isolate 6 harboring N23S, K36E, R89Q, +1G 437-438 = Stop 225 mutations in thymidine kinase and S33G, A330R, A646T, S1123L, P1124H, T1208A, R1229I mutations in DNA polymerase infected in african green monke
|
[PMID: 20733037]
|
Vero
|
EC50 |
3 μM
Compound: Acycloguanosine
|
Antiviral activity against Human herpesvirus 1 KOS ATCC VR-1493 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining
Antiviral activity against Human herpesvirus 1 KOS ATCC VR-1493 infected in African green monkey Vero 76 cells assessed as reduction of virus-plaque formation after 3 days by crystal violet staining
|
[PMID: 26119992]
|
Vero
|
EC50 |
|
Antiviral activity against Human herpesvirus 1 strain KOS infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 3 days using crystal violet staining
Antiviral activity against Human herpesvirus 1 strain KOS infected in african green monkey Vero 76 cells assessed as reduction of virus-induced plaque formation after 3 days using crystal violet staining
|
[PMID: 22047799]
|
Vero
|
EC50 |
|
Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay
Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay
|
[PMID: 20359898]
|
Vero
|
EC50 |
|
Antiviral activity against Human herpesvirus 1 infected African green monkey Vero 76 cells assessed as reduction in plaque number treated after viral infection measured after 3 days by plaque reduction assay
Antiviral activity against Human herpesvirus 1 infected African green monkey Vero 76 cells assessed as reduction in plaque number treated after viral infection measured after 3 days by plaque reduction assay
|
10.1007/s00044-012-0342-1
|
Vero
|
IC50 |
|
Antiviral activity against acyclovir-sensitive HSV1 KOS isolate replication in african green monkey Vero cells by plaque reduction assay
Antiviral activity against acyclovir-sensitive HSV1 KOS isolate replication in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19010684]
|
Vero
|
IC50 |
3.5 μM
Compound: acyclovir
|
Antiviral activity against herpes simplex virus type 1 KOS (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
Antiviral activity against herpes simplex virus type 1 KOS (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
|
[PMID: 16134946]
|
Vero
|
IC50 |
31 μM
Compound: Acyclovir
|
Antiviral activity against Herpes simplex virus 2 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect after 24 hrs by crystal violet staining based assay
Antiviral activity against Herpes simplex virus 2 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect after 24 hrs by crystal violet staining based assay
|
[PMID: 31975590]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 isolate 7 harboring N23S, K36E, R89Q, +1C 464-465 = Stop 228 mutations in thymidine kinase and S33G, A330R, P1124H, T1208A, A870G mutations in DNA polymerase infected in african green monkey Vero cells by
Antiviral activity against Herpes simplex virus 1 isolate 7 harboring N23S, K36E, R89Q, +1C 464-465 = Stop 228 mutations in thymidine kinase and S33G, A330R, P1124H, T1208A, A870G mutations in DNA polymerase infected in african green monkey Vero cells by
|
[PMID: 20733037]
|
Vero
|
IC50 |
|
Antiviral activity against acyclovir-resistant HSV1 KOS-M isolate replication in african green monkey Vero cells by plaque reduction assay
Antiviral activity against acyclovir-resistant HSV1 KOS-M isolate replication in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19010684]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 isolate 13 harboring, M183I mutations in thymidine kinase and A9T, P15S, R41H, L60P, E139K, A232T mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Herpes simplex virus 2 isolate 13 harboring, M183I mutations in thymidine kinase and A9T, P15S, R41H, L60P, E139K, A232T mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 1 isolate 3 harboring N23S, K36E, R89Q, A265T, Y53D mutations in thymidine kinase and S33G, A330R, V905M, E1005K mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction as
Antiviral activity against Herpes simplex virus 1 isolate 3 harboring N23S, K36E, R89Q, A265T, Y53D mutations in thymidine kinase and S33G, A330R, V905M, E1005K mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction as
|
[PMID: 20733037]
|
Vero
|
IC50 |
4.21 μg/mL
Compound: acyclovir
|
Antiviral activity against Herpes simplex virus 2 infected in african green monkey Vero cells assessed inhibition of virus-induced effect after 48 hrs by MTT assay
Antiviral activity against Herpes simplex virus 2 infected in african green monkey Vero cells assessed inhibition of virus-induced effect after 48 hrs by MTT assay
|
[PMID: 11678658]
|
Vero
|
IC50 |
4.4 μM
Compound: acyclovir
|
Antiviral activity against herpes simplex virus type 1 KOS (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
Antiviral activity against herpes simplex virus type 1 KOS (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
|
[PMID: 16134946]
|
Vero
|
EC50 |
4.4 μM
Compound: Acyclovir
|
Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50%
Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50%
|
[PMID: 11585457]
|
Vero
|
EC50 |
40 μg/mL
Compound: 1b (Acyclovir)
|
Concentration required to inhibit plaque formation by HSV-1 strain KOSSB (TK-) in monolayers of vero cells
Concentration required to inhibit plaque formation by HSV-1 strain KOSSB (TK-) in monolayers of vero cells
|
[PMID: 11677126]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 isolate 25 harboring I101S mutations in thymidine kinase and D785N, V544A mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Herpes simplex virus 2 isolate 25 harboring I101S mutations in thymidine kinase and D785N, V544A mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 isolate 12 harboring G39E, N78D, L140F, S66P, A72S mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
Antiviral activity against Herpes simplex virus 2 isolate 12 harboring G39E, N78D, L140F, S66P, A72S mutations in thymidine kinase and A9T, P15S, L60P mutations in DNA polymerase infected in african green monkey Vero cells by plaque reduction assay
|
[PMID: 20733037]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs
|
[PMID: 17438061]
|
Vero
|
IC50 |
5.4 μM
Compound: acyclovir
|
Antiviral activity against herpes simplex virus type 1 Patton (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
Antiviral activity against herpes simplex virus type 1 Patton (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO
|
[PMID: 16134946]
|
Vero
|
EC50 |
530 μM
Compound: 1, Acyclovir, ACV
|
Antiviral activity against acyclovir-resistant HSV1 L2 infected in Vero E6 cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
Antiviral activity against acyclovir-resistant HSV1 L2 infected in Vero E6 cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
|
[PMID: 22954898]
|
Vero
|
EC50 |
|
Antiviral activity against Herpes simplex virus 2 MS infected in Vero cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
Antiviral activity against Herpes simplex virus 2 MS infected in Vero cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
|
[PMID: 23419738]
|
Vero
|
EC50 |
|
Antiviral activity against HSV1 KOS in african green monkey Vero cells by plaque reduction assay
Antiviral activity against HSV1 KOS in african green monkey Vero cells by plaque reduction assay
|
[PMID: 17981031]
|
Vero
|
EC50 |
6.2 μM
Compound: Acyclovir
|
Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell monolayers of HSV-2 MS Vero cells by 50%
Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell monolayers of HSV-2 MS Vero cells by 50%
|
[PMID: 11585457]
|
Vero
|
EC50 |
|
Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay
Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay
|
[PMID: 26460883]
|
Vero
|
IC50 |
|
Antiviral activity against acyclovir-resistant HSV1 K143 isolate replication in african green monkey Vero cells by plaque reduction assay
Antiviral activity against acyclovir-resistant HSV1 K143 isolate replication in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19010684]
|
Vero
|
CC50 |
|
Cytotoxicity against african green monkey Vero cells after 72 hrs by XTT assay
Cytotoxicity against african green monkey Vero cells after 72 hrs by XTT assay
|
[PMID: 21376603]
|
Vero
|
IC50 |
|
Antiviral activity against acyclovir-resistant HSV1 L182 isolate replication in african green monkey Vero cells by plaque reduction assay
Antiviral activity against acyclovir-resistant HSV1 L182 isolate replication in african green monkey Vero cells by plaque reduction assay
|
[PMID: 19010684]
|
Vero
|
CC50 |
|
Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 72 hr by MTT assay
Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 72 hr by MTT assay
|
10.1007/s00044-007-9035-6
|
Vero
|
CC50 |
|
Cytotoxicity against Vero cells by MTT assay
Cytotoxicity against Vero cells by MTT assay
|
[PMID: 16321530]
|
Vero 76
|
CC50 |
|
Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay
Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay
|
[PMID: 29028528]
|
Vero 76
|
CC50 |
|
Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay
Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay
|
[PMID: 27161176]
|
Vero 76
|
CC50 |
|
Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method
Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method
|
[PMID: 25913116]
|
Vero 76
|
CC50 |
|
Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay
Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay
|
[PMID: 25082514]
|
Vero 76
|
CC50 |
|
Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method
Cytotoxicity against mock-infected African green monkey Vero 76 cells assessed as reduction in proliferation after 48 to 96 hrs by MTT method
|
[PMID: 25014745]
|
Vero 76
|
EC50 |
|
Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay
Antiviral activity against CVB-5 virus Faulkner ATCC VR-185 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay
|
[PMID: 26479028]
|
Vero 76
|
EC50 |
|
Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay
Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay
|
[PMID: 26443549]
|
Vero 76
|
EC50 |
|
Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay
Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay
|
[PMID: 19482481]
|
Vero 76
|
CC50 |
|
Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method
Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method
|
[PMID: 26443549]
|
Vero 76
|
EC50 |
|
Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay
Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay
|
[PMID: 26443549]
|
Vero 76
|
EC50 |
|
Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay
Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay
|
[PMID: 19482481]
|
Vero 76
|
EC50 |
|
Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay
Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay
|
[PMID: 26443549]
|
Vero 76
|
EC50 |
|
Antiviral activity against Vaccinia virus Elstree infected in Vero 76 cells after 3 days by crystal violet staining based plaque reduction assay
Antiviral activity against Vaccinia virus Elstree infected in Vero 76 cells after 3 days by crystal violet staining based plaque reduction assay
|
[PMID: 27161176]
|
Vero 76
|
CC50 |
13 μM
Compound: Acycloguanosine
|
Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining
Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining
|
[PMID: 26119992]
|
Vero 76
|
EC50 |
3 μM
Compound: Acycloguanosine
|
Antiviral activity against Herpes simplex virus type 1 KOS ATCC VR-1493 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 3 days by crystal violet staining
Antiviral activity against Herpes simplex virus type 1 KOS ATCC VR-1493 infected in african green monkey Vero-76 cells assessed as reduction in viral plaque after 3 days by crystal violet staining
|
[PMID: 22513121]
|
Vero 76
|
EC50 |
|
Antiviral activity against Human herpesvirus 1 infected African green monkey Vero76 cells assessed as reduction of virus-induced plaque reduction after 3 days by MTT assay
Antiviral activity against Human herpesvirus 1 infected African green monkey Vero76 cells assessed as reduction of virus-induced plaque reduction after 3 days by MTT assay
|
10.1007/s00044-010-9513-0
|
Vero 76
|
EC50 |
|
Antiviral activity against HSV-1 KOS ATCC VR- 1493 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay
Antiviral activity against HSV-1 KOS ATCC VR- 1493 infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay
|
[PMID: 26479028]
|
Vero 76
|
EC50 |
|
Antiviral activity against Human herpesvirus 1 strain KOS ATCC VR- 1493 infected in Vero 76 cells after 3 days by plaque reduction assays
Antiviral activity against Human herpesvirus 1 strain KOS ATCC VR- 1493 infected in Vero 76 cells after 3 days by plaque reduction assays
|
[PMID: 25014745]
|
Vero 76
|
EC50 |
|
Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay
Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay
|
[PMID: 19482481]
|
Vero C1008
|
CC50 |
> 1000 μM
Compound: Acyclovir
|
Cytotoxicity against mock-infected African green monkey Vero E6 cells assessed as inhibition of cell survival after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay
Cytotoxicity against mock-infected African green monkey Vero E6 cells assessed as inhibition of cell survival after 3 days by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay
|
[PMID: 26048809]
|